Academic Journal
The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study
| العنوان: | The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study |
|---|---|
| المؤلفون: | Netti, Giuseppe Stefano, Soccio, Piera, Catalano, Valeria, De Luca, Federica, Khalid, Javeria, Camporeale, Valentina, Moriondo, Giorgia, Papale, Massimo, Scioscia, Giulia, Corso, Gaetano, Foschino, Maria Pia, Lo Caputo, Sergio, Lacedonia, Donato, Ranieri, Elena |
| المساهمون: | Netti, Giuseppe Stefano, Soccio, Piera, Catalano, Valeria, De Luca, Federica, Khalid, Javeria, Camporeale, Valentina, Moriondo, Giorgia, Papale, Massimo, Scioscia, Giulia, Corso, Gaetano, Foschino, Maria Pia, Lo Caputo, Sergio, Lacedonia, Donato, Ranieri, Elena |
| سنة النشر: | 2024 |
| المجموعة: | Università degli Studi di Foggia: CINECA IRIS Institutional Research Information System |
| مصطلحات موضوعية: | ANA, COVID-19, HALP score, SARS-CoV-2, antinuclear antibodies |
| الوصف: | The immune system's amplified response to SARS-CoV-2 may lead to the production of autoantibodies, but their specific impact on disease severity and outcome remains unclear. This study aims to assess if hospitalized COVID-19 patients face a worse prognosis based on ANA presence, even without autoimmune diseases. We performed a retrospective, single-center, observational cohort study, enrolling 638 COVID-19 patients hospitalized from April 2020 to March 2021 at Hospital "Policlinico Riuniti" of Foggia (Italy). COVID-19 patients with a positive ANA test exhibited a significantly lower 30-day survival rate (64.4% vs. 83.0%) and a higher likelihood of severe respiratory complications during hospitalization than those with negative ANA screening (35.4% vs. 17.0%) (p < 0.001). The association between poor prognosis and ANA status was identified by calculating the HALP score (Hemoglobin-Albumin-Lymphocyte-Platelet), which was lower in COVID-19 patients with a positive ANA test compared to ANA-negative patients (108.1 +/- 7.4 vs. 218.6 +/- 11.2 AU; p < 0.011). In detail, COVID-19 patients with a low HALP showed a lower 30-day survival rate (99.1% vs. 83.6% vs. 55.2% for high, medium, and low HALP, respectively; p < 0.001) and a higher incidence of adverse respiratory events compared to those with high and medium HALP (13.1% vs. 35.2% vs. 64.6% for high, medium, and low HALP, respectively; p < 0.001). In summary, ANA positivity in COVID-19 patients appears to be linked to a more aggressive disease phenotype with a reduced survival rate. Furthermore, we propose that the HALP score could serve as a valuable parameter to assess prognosis for COVID-19 patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38927513; info:eu-repo/semantics/altIdentifier/wos/WOS:001254914800001; volume:12; issue:6; journal:BIOMEDICINES; https://hdl.handle.net/11369/455209; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85197238612 |
| DOI: | 10.3390/biomedicines12061306 |
| الاتاحة: | https://hdl.handle.net/11369/455209 https://doi.org/10.3390/biomedicines12061306 |
| رقم الانضمام: | edsbas.F01E0BCF |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/biomedicines12061306 |
|---|